The global blood plasma derivatives market was valued at $ 36,471.9 million in 2020, and is projected to reach $ 89,767 million by 2030, registering a CAGR of 9.4% from 2021 to 2030.
Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.
The major factor that contributes toward the growth of the blood plasma derivatives market is increase in prevalence of life-threatening diseases such as immunodeficiency disorders and hemophilia. Moreover, other factors that boost the market growth include increase in awareness for blood & plasma donation, rise in geriatric population, and high adoption of blood plasma derivatives products. However, high cost of treatment and risks of side effects associated with the use of plasma derivatives hamper the market growth. Conversely, development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.
The blood plasma derivatives market is segmented on the basis of type, application, end user, and region. Based on type, the market is fragmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The applications covered in the study include hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other applications. By end user, the market is classified into hospitals, clinics, and other end users. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.
The major factor that contributes toward the growth of the blood plasma derivatives market is increase in prevalence of life-threatening diseases such as immunodeficiency disorders and hemophilia. Moreover, other factors that boost the market growth include increase in awareness for blood & plasma donation, rise in geriatric population, and high adoption of blood plasma derivatives products. However, high cost of treatment and risks of side effects associated with the use of plasma derivatives hamper the market growth. Conversely, development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.
The blood plasma derivatives market is segmented on the basis of type, application, end user, and region. Based on type, the market is fragmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The applications covered in the study include hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other applications. By end user, the market is classified into hospitals, clinics, and other end users. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the blood plasma derivative market size along with the current trends and future estimations to elucidate the imminent investment pockets
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global blood plasma derivative market
KEY MARKET SEGMENTS
By Type
- Albumin
- Factor VIII
- Factor IX
- Immunoglobulin
- Hyperimmune Globulin
- Others
By Application
- Hemophilia
- Hypogammaglobulinemia
- Immunodeficiency Diseases
- Von Willebrand'S Disease
- Other Application
By End User
- Hospitals
- Clinics
- Other End Users
By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Bayer AG
- Biotest AG
- CSL limited
- Fusion Health Care Pvt Ltd
- Grifols ,SA
- Kedrion Biopharma ,Inc
- LFB SA
- Octapharma AG
- Sanofi
- Takeda
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Landscape
Chapter 4: Blood Plasma Derivatives Market, by Type
Chapter 5: Blood Plasma Derivatives Market, by Application
Chapter 6: Blood Plasma Derivatives Market, by End-user
Chapter 7: Blood Plasma Derivatives Market, by Region
Chapter 8: Company Profiles
List of Tables
List of Figures
Executive Summary
According to a new report titled, “Blood Plasma Derivatives Market by Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global blood plasma derivatives market size was valued at $36.471 billion in 2020, and is estimated to reach $89.767 billion by 2030, growing at a CAGR of 9.4% from 2021 to 2030.Blood plasma is clear liquid component of blood in which red blood cells, white blood cells, and platelets are suspended. It plays a vital role in maintaining proper pH balance in the body and transporting nutrients throughout the body. It is composed of more than 100 different proteins, including albumin, fibrinogen, immunoglobulins, protease inhibitors, and clotting factors. Plasma derivatives are products that are derived from blood plasma on fractionation, and are widely used to treat variety of diseases. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III concentrate.
The factors that drive the growth of the blood plasma derivatives market include increase in prevalence of life-threatening diseases such as immunodeficiency diseases & hemophilia, rise in awareness toward blood & plasma donation, and growth in adoption of blood plasma derivatives products.
Moreover, other factors that are responsible for the growth of the plasma derived derivatives are increase in awareness of blood & plasma donation, rise in geriatric population, & higher adoption of the blood plasma derivative products. Furthermore, market players are focused on manufacturing of different blood plasma derivatives product. For instance, in April 2020, Biotest, a pharmaceutical company, announced the launch of a life saving medicine, which is derived blood plasma of COVID-19 patient. Moreover, surge in prevalence of geriatric population, who are more vulnerable to chronic disease escalate the blood plasma derivatives market growth.
In addition, rise in disposable income and development of the pharmaceutical sector for manufacturing of plasma derived products is anticipated to drive growth of the market. In addition, expansion of many clinical studies on various types of products to evaluate their safety and efficacy propels the growth of the market. For instance, in February 2022, the U.S Food and Drug Administration (FDA), announced clinical research activities in order to enhance the safety of blood plasma derive product, such as protein used to treat immune system disorder and clotting disorder.
Rise in number of approval for plasma derived products and increase in number of pharmaceutical manufacturing companies are the key factors that further boost growth of the blood plasma derivatives market. However, high cost of plasma derivative-based treatment and risk of side effects associated after using plasma derivatives impede the market growth. Conversely, the development of superior methods for preservation of plasma derivatives along with advanced processes for fractionation and presence of untapped market in emerging economies are expected to provide lucrative growth opportunities for the market.
The blood plasma derivatives market is segmented into type, application, end user, and region. On the basis of type, the market is segregated into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulin segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to rise in R&D activities related to manufacturing of plasma derived products in the pharmaceutical sector and increase in prevalence of immune disease.
Depending on application, the blood plasma derivatives market is classified into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other applications. The immunodeficiency diseases segment is expected to lead during the forecast period, owing to increase in prevalence of immune diseases and development of advanced drugs by the pharmaceutical industry. By end user, the market is categorized into hospital, clinic, and other end users. The hospital segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to surge in number of hospital, and initiatives taken by governments & private organizations to develop healthcare sector.
The COVID-19 outbreak is anticipated to have a positive impact on growth of the global plasma derivatives market. The COVID-19 pandemic has stressed healthcare systems in the world. Meanwhile, in August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for convalescent plasma for the treatment of hospitalized patients with COVID-19. The antibodies or plasma are collected from donors who have recovered from COVID-19. It may contain antibodies to SARS-CoV-2, which help suppress viral replication. Thus, upsurge in demand for plasma derived product for the treatment of infectious diseases positively impacted the growth of the market.
Key Findings Of The Study
- By type, the immunodeficiency disorder was the highest contributor to the blood plasma derivatives market in 2020
- On the basis of application, other application dominated the market in 2020, and is expected to continue this trend during the forecast period
- Depending on end user, the hospital segment led the blood plasma derivatives market in 2020
- Region wise, North America garnered the largest revenue share in 2020, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
- North America garnered a major share of the blood plasma derivatives market in 2020, and is expected to continue to dominate during the forecast period, owing to increase in number of approval for blood plasma derivative product and rise in number of key players to manufacture plasma derived drug. However, Asia-Pacific is expected to register highest CAGR of 110% from 2021 to 2030, owing to increase in prevalence of immune disease, rise in awareness toward plasma derivatives, and surge in healthcare expenditure
Companies Mentioned
- Bayer AG
- Biotest AG
- CSL limited
- Fusion Health Care Pvt. Ltd
- Grifols
- Kedrion Biopharma ,Inc.
- LFB S.A
- Octapharma AG
- Sanofi
- Takeda.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 258 |
| Published | February 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 36471.9 million |
| Forecasted Market Value ( USD | $ 89767 million |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
